(LML) 19th International Leprosy Congress Beijing 2016

Leprosy Mailing List – March 5, 2016

Ref.:   (LML) 19th International Leprosy Congress Beijing 2016

From:  Ruth Butlin, Nilphmari, Bangladesh

---

Dear Editor,

I would like to suggest a few questions to be considered for the clinical leprosy session (request Dr. Ben Naafs, LML February 4, 2016):

1. Does anyone have tried and tested (preferably evidence-based) guidelines on “managing Leprosy reactions in Children", giving appropriate dosages and durations of steroids and any evidence on incidence of adverse effects?

2. Does anyone anywhere routinely use the "clinical prediction rule" for identifying leprosy affected people at more risk of having new nerve function impairment within 24m of diagnosis, in order to give them more attention (monitoring and care) including in the 6-18m period after competing MDT? It should allow optimal use of sparse human resources for maximum benefit of patients at highest risk.

If not, why not?

3. Does anyone have guidelines for chemotherapy of highly smear positive cases with impaired liver function which contra-indicates most of first and second line anti-leprosy drugs? Is there any evidence base for managing this problem?

Thank you.

 

Yours sincerely,

C Ruth Butlin

TLM Bangladesh

---

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

Dit e-mailbericht is verzonden vanaf een virusvrije computer die wordt beschermd door Avast. www.avast.com